Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 PROGRESSIVE MYOCLONUS EPILEPSY WITH LAFORA BODIES. CLINICAL-PATHOLOGICAL FEATURES.

Literature DB >> 14092647

PROGRESSIVE MYOCLONUS EPILEPSY WITH LAFORA BODIES. CLINICAL-PATHOLOGICAL FEATURES.

H DE JAGER.

Abstract

Keywords: ADOLESCENCE; BRAIN; CHILD; CONSANGUINITY; ELECTROENCEPHALOGRAPHY; EPILEPSY, PETIT MAL; PATHOLOGY

Mesh：

Year: 1963 PMID： 14092647 DOI： 10.1111/j.1528-1157.1963.tb05214.x

Source DB: PubMed Journal: Epilepsia ISSN： 0013-9580 Impact factor: 5.864

Keyword Cloud
Cited

× No keyword cloud information.

19 in total

1. The myocardium in Lafora disease.

Authors: S Yokoi; Y Aihara; S Maeda
Journal: Acta Neuropathol Date: 1975-12-30 Impact factor: 17.088

2. Targeting Pathogenic Lafora Bodies in Lafora Disease Using an Antibody-Enzyme Fusion.

Authors: M Kathryn Brewer; Annette Uittenbogaard; Grant L Austin; Dyann M Segvich; Anna DePaoli-Roach; Peter J Roach; John J McCarthy; Zoe R Simmons; Jason A Brandon; Zhengqiu Zhou; Jill Zeller; Lyndsay E A Young; Ramon C Sun; James R Pauly; Nadine M Aziz; Bradley L Hodges; Tracy R McKnight; Dustin D Armstrong; Matthew S Gentry
Journal: Cell Metab Date: 2019-07-25 Impact factor: 27.287

Review 3. [Lafora disease: a review of the literature].

Authors: L Desdentado; R Espert; P Sanz; J Tirapu-Ustarroz
Journal: Rev Neurol Date: 2019-01-16 Impact factor: 0.870

Review 4. The history of progressive myoclonus epilepsies.

Authors: Pierre Genton; Pasquale Striano; Berge A Minassian
Journal: Epileptic Disord Date: 2016-09-01 Impact factor: 1.819

5. Sodium selenate treatment improves symptoms and seizure susceptibility in a malin-deficient mouse model of Lafora disease.

Authors: Gentzane Sánchez-Elexpuru; José M Serratosa; Marina P Sánchez
Journal: Epilepsia Date: 2017-01-18 Impact factor: 5.864

10. 4-Phenylbutyric acid and metformin decrease sensitivity to pentylenetetrazol-induced seizures in a malin knockout model of Lafora disease.

Authors: Gentzane Sánchez-Elexpuru; José M Serratosa; Pascual Sanz; Marina P Sánchez
Journal: Neuroreport Date: 2017-03-22 Impact factor: 1.837

PROGRESSIVE MYOCLONUS EPILEPSY WITH LAFORA BODIES. CLINICAL-PATHOLOGICAL FEATURES.

1. The myocardium in Lafora disease.

2. Targeting Pathogenic Lafora Bodies in Lafora Disease Using an Antibody-Enzyme Fusion.

Review 3. [Lafora disease: a review of the literature].

Review 4. The history of progressive myoclonus epilepsies.

5. Sodium selenate treatment improves symptoms and seizure susceptibility in a malin-deficient mouse model of Lafora disease.

Review 6. [Liver in progressive myoclonus epilepsy (Lafora's disease) (author's transl)].

7. [Histochemical study of Lafora's bodies].

8. [On the ultrastructure of myoclonic bodies].

9. Progressive myoclonus epilepsy without Lafora bodies.

10. 4-Phenylbutyric acid and metformin decrease sensitivity to pentylenetetrazol-induced seizures in a malin knockout model of Lafora disease.